Now, already in clinic for over a decade, anti-CD19 CAR-T cells have shown remission rates as high as 90% in pediatric ALL and 50%–90% in adult B-cell malignancies (14–16). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.